EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE

被引：0
|
作者：
Zackova, D. [1 ]
Klamova, H. [3 ]
Doubek, M. [1 ]
Pospisil, Z. [2 ]
Dvorakova, D. [1 ]
Jurcek, T. [1 ]
Moravcova, J. [3 ]
Machova, K. [3 ]
Rulcova, J. [3 ]
Dobesova, B. [1 ]
Rysava, J. [3 ]
Cetkovsky, P. [3 ]
Razga, F. [1 ]
Mayer, J. [1 ]
机构：
[1] Univ Hosp, Dept Internal Med & Hematooncol, Brno, Czech Republic
[2] Masaryk Univ, Dept Math & Stat, Brno, Czech Republic
[3] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0858
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [1] A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line
    Castagnetti, Fausto
    Di Raimondo, Francesco
    de Vivo, Antonio
    Spitaleri, Antonio
    Gugliotta, Gabriele
    Fabbiano, Francesco
    Capodanno, Isabella
    Mannina, Donato
    Salvucci, Marzia
    Antolino, Agostino
    Marasca, Roberto
    Musso, Maurizio
    Crugnola, Monica
    Impera, Stefana
    Trabacchi, Elena
    Musolino, Caterina
    Cavazzini, Francesco
    Mineo, Giuseppe
    Tosi, Patrizia
    Tomaselli, Carmela Anna Maria
    Rizzo, Michele
    Siragusa, Sergio
    Fogli, Miriam
    Ragionieri, Riccardo
    Zironi, Alessandro
    Soverini, Simona
    Martinelli, Giovanni
    Cavo, Michele
    Vigneri, Paolo
    Stagno, Fabio
    Rosti, Gianantonio
    Baccarani, Michele
    BLOOD, 2016, 128 (22)
  • [2] A population-based study of chronic myeloid leukemia patients treated with imatinib in first line
    Castagnetti, Fausto
    Di Raimondo, Francesco
    De Vivo, Antonio
    Spitaleri, Antonio
    Gugliotta, Gabriele
    Fabbiano, Francesco
    Capodanno, Isabella
    Mannina, Donato
    Salvucci, Marzia
    Antolino, Agostino
    Marasca, Roberto
    Musso, Maurizio
    Crugnola, Monica
    Impera, Stefana
    Trabacchi, Elena
    Musolino, Caterina
    Cavazzini, Francesco
    Mineo, Giuseppe
    Tosi, Patrizia
    Tomaselli, Carmela
    Rizzo, Michele
    Siragusa, Sergio
    Fogli, Miriam
    Ragionieri, Riccardo
    Zironi, Alessandro
    Soverini, Simona
    Martinelli, Giovanni
    Cavo, Michele
    Vigneri, Paolo
    Stagno, Fabio
    Rosti, Gianantonio
    Baccarani, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (01) : 82 - 87
  • [3] Cost-effectiveness of imatinib (GLEEVEC) as first-line treatment in chronic myeloid leukemia (CML)
    El Quagari, K
    Talbot, W
    Baladi, JF
    VALUE IN HEALTH, 2004, 7 (06) : 669 - 669
  • [4] IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. CAN WE COMPARE THE REAL-LIFE DATA TO CLINICAL TRIAL RESULTS?
    Zackova, D.
    Klamova, H.
    Dusek, L.
    Muzik, J.
    Dobesova, B.
    Rysava, J.
    Racil, Z.
    Doubek, M.
    Dvorakova, D.
    Jurcek, T.
    Razga, F.
    Moravcova, J.
    Polakova, K. Machova
    Rulcova, J.
    Cetkovsky, P.
    Mayer, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 350 - 350
  • [5] Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
    Gemelli, Maria
    Elli, Elena Maria
    Elena, Chiara
    Iurlo, Alessandra
    Intermesoli, Tamara
    Maffioli, Margherita
    Pungolino, Ester
    Carraro, Maria Cristina
    D'Adda, Mariella
    Lunghi, Francesca
    Anghileri, Michela
    Polverelli, Nicola
    Rossi, Marianna
    Bacciocchi, Mattia
    Bono, Elisa
    Bucelli, Cristina
    Passamonti, Francesco
    Antolini, Laura
    Gambacorti-Passerini, Carlo
    BLOOD RESEARCH, 2020, 55 (03) : 139 - 145
  • [6] Efficacy of the expanded treatment program with imatinib mesylate in 109 patients with chronic myeloid leukemia (CML)
    Vysotskaya, L.
    Golenkov, A.
    Trifonova, E.
    Chernykh, Y.
    Lutskaya, T.
    Inyutkina, N.
    Chukavina, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 532 - 532
  • [7] EVALUATION OF CLINICAL EFFICACY AND SAFETY OF GENERIC IMATINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
    Cojbasic, I.
    Macukanovic-Golubovic, L.
    Vucic, M.
    Govedarovic, N.
    HAEMATOLOGICA, 2016, 101 : 734 - 735
  • [8] Efficacy and safety of imatinib treatment in elederly patients with chronic myeloid leukemia.
    Martino, B
    Vincelli, L
    Ronco, F
    Modafferi, B
    Princi, D
    Morabito, F
    Izzo, B
    Pane, F
    Nobile, F
    BLOOD, 2004, 104 (11) : 254B - 254B
  • [9] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Wei, Guoqing
    Rafiyath, Shamudheen
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [10] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
12345